Anticoagulation: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery

Chest

Volumn 128, Issue 2 SUPPL., 2005, Pages 24S-27S

  Epstein, Andrew E ^a,f   Alexander, John C ^b   Gutterman, David D ^c   Maisel, William ^d   Wharton, J Marcus ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d HARVARD UNIVERSITY   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; HEPARIN; WARFARIN;

AGED; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SURGERY; HIGH RISK PATIENT; HUMAN; MEDICAL DECISION MAKING; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 23744466462     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.2_suppl.24S     Document Type: Article

References (19)

1. Pantely GA, Goodnight SH Jr, Rahimtoola SH, et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med 1979; 301:962-966
2. Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patencv. N Engl J Med 1982; 307:73-78
3. McEnany MT, Salzman EW, Mundth ED, et al. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg 1982; 83:81-89
4. Chevigne M, David JL, Rigo P, et al. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg 1984; 37:371-378
5. Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation. Lancet 1984; 1:1261-1264
6. Brooks N, Wright J, Sturridge M. et al. Randomised placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. Br Heart J 1985; 53:201-207
7. Rothlin ME, Pfluger N, Speiser K, et al. Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion. Eur Heart J 1985; 6:168-175
8. Sanz G, Pajaron A, Alegria E, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole: Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC). Circulation 1990; 82:765-773.
9. Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting: Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990; 15:15-20
10. Teoh KH, Weisel RD, Ivanov J, et al. Dipyridamole for coronary artery bypass surgery. Thromb Res 1990; 12(suppl):91-99
11. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery, a placebo-controlled, randomized study. Circulation 1991; 83:1526-1533
12. van der Meer J, Hillege HL, Kootstra GJ, et al. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants: the CABADAS Research Group of the Intel-university Cardiology Institute of The Netherlands. Lancet 1993; 342:257-264
13. Fuster V, Rydén LE, Asinger RW, et al ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001; 28:1231-1266
14. American College of Chest Physicians. Sixth ACCP Consensus Conference on Antithroinbotic Therapy. Chest 2001; 119(suppl):1S-370S
15. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501
16. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes of stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 2000; 109:45-51
17. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135:1061-1073
18. Petty GW, Brown RD, Whisnant JP, et al. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population-based study. Ann Intern Med 1999; 130:14-22
19. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationship with long-term therapy. Chest 2002; 121:19-23